gsk2141795 and Skin-Neoplasms

gsk2141795 has been researched along with Skin-Neoplasms* in 1 studies

Trials

1 trial(s) available for gsk2141795 and Skin-Neoplasms

Article	Year
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment cell & melanoma research, 2018, Volume: 31, Issue:1 Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAF Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diamines; Female; GTP Phosphohydrolases; Humans; Male; MAP Kinase Kinase 1; Melanoma; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridones; Pyrimidinones; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult	2018

Article

Year

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Pigment cell & melanoma research, 2018, Volume: 31, Issue:1

Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAF

Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diamines; Female; GTP Phosphohydrolases; Humans; Male; MAP Kinase Kinase 1; Melanoma; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridones; Pyrimidinones; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult

2018